104 related articles for article (PubMed ID: 21425536)
1. [Post-licensure safety surveillance for influenza A(H1N1) pandemic vaccines: first results].
Jacquet A; Ouaret S; Kreft-Jaïs C; Castot A
Rev Prat; 2010 Dec; 60(10):1392-4. PubMed ID: 21425536
[No Abstract] [Full Text] [Related]
2. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.
Liang XF; Li L; Liu DW; Li KL; Wu WD; Zhu BP; Wang HQ; Luo HM; Cao LS; Zheng JS; Yin DP; Cao L; Wu BB; Bao HH; Xu DS; Yang WZ; Wang Y
N Engl J Med; 2011 Feb; 364(7):638-47. PubMed ID: 21288090
[TBL] [Abstract][Full Text] [Related]
3. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.
Kurz X; Domergue F; Slattery J; Segec A; Szmigiel A; Hidalgo-Simon A
Vaccine; 2011 Jun; 29(26):4378-87. PubMed ID: 21501644
[TBL] [Abstract][Full Text] [Related]
4. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
[TBL] [Abstract][Full Text] [Related]
5. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.
Parretta E; Ianniello B; Ferrazin F; Rossi F; Capuano A
Vaccine; 2011 May; 29(20):3708-13. PubMed ID: 21406267
[TBL] [Abstract][Full Text] [Related]
6. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
Yih WK; Lee GM; Lieu TA; Ball R; Kulldorff M; Rett M; Wahl PM; McMahill-Walraven CN; Platt R; Salmon DA
Am J Epidemiol; 2012 Jun; 175(11):1120-8. PubMed ID: 22582207
[TBL] [Abstract][Full Text] [Related]
8. Vaccine safety.
Labadie J
Int J Risk Saf Med; 2011; 23(2):113-5. PubMed ID: 21673419
[TBL] [Abstract][Full Text] [Related]
9. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan.
Huang WT; Chen WW; Yang HW; Chen WC; Chao YN; Huang YW; Chuang JH; Kuo HS
Vaccine; 2010 Oct; 28(44):7161-6. PubMed ID: 20804804
[TBL] [Abstract][Full Text] [Related]
10. Safety of influenza vaccines in pregnant women.
Munoz FM
Am J Obstet Gynecol; 2012 Sep; 207(3 Suppl):S33-7. PubMed ID: 22920057
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010.
Folkenberg M; Callréus T; Svanström H; Valentiner-Branth P; Hviid A
Vaccine; 2011 Feb; 29(6):1180-4. PubMed ID: 21172382
[TBL] [Abstract][Full Text] [Related]
12. Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting.
Carvajal A; Ortega PG; Sáinz M; Velasco V; Salado I; Arias LH; Eiros JM; Rubio AP; Castrodeza J
Vaccine; 2011 Jan; 29(3):519-22. PubMed ID: 21112311
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring.
Härmark L; van Hunsel F; Hak E; van Grootheest K
Vaccine; 2011 Feb; 29(10):1941-7. PubMed ID: 21236235
[TBL] [Abstract][Full Text] [Related]
15. [Pandemic vaccines].
Floret D
Arch Pediatr; 2010 Jun; 17(6):906-7. PubMed ID: 20654954
[No Abstract] [Full Text] [Related]
16. NSW Annual Adverse Events Following Immunisation Report, 2009.
Mahajan D; Campbell-Lloyd S; Roomiani I; Menzies RI
N S W Public Health Bull; 2010; 21(9-10):224-33. PubMed ID: 21211475
[TBL] [Abstract][Full Text] [Related]
17. Serious adverse reactions should be further monitored after influenza A (H1N1) vaccination among children: postmarketing experience with 570,000 vaccinations between October 2009 and August 2010 in Guangzhou, China.
Fu C; Xu J; Tan H; Wang M
Pediatr Infect Dis J; 2011 Jul; 30(7):631-2. PubMed ID: 21673552
[No Abstract] [Full Text] [Related]
18. 2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey.
Lacroix I; Damase-Michel C; Kreft-Jais C; Castot A; Montastruc JL;
Vaccine; 2011 Feb; 29(7):1357-8. PubMed ID: 21185422
[No Abstract] [Full Text] [Related]
19. Risk of fatal adverse events after H1N1 influenza vaccination.
Nakada H; Narimatsu H; Tsubokura M; Murashige N; Matsumura T; Kodama Y; Kishi Y; Kami M
Clin Infect Dis; 2010 Jun; 50(11):1548-9. PubMed ID: 20433361
[No Abstract] [Full Text] [Related]
20. Avoiding Guillan-Barré Syndrome following swine origin pandemic H1N1 2009 influenza vaccination.
Eisen DP; McBryde ES
J Infect Dis; 2009 Nov; 200(10):1627-8. PubMed ID: 19857155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
